In the original article, there was a mistake in [Figure 1A](#F1){ref-type="fig"} and [Figure 2A](#F2){ref-type="fig"} as published. In [Figure 1A](#F1){ref-type="fig"}, two panels of the 12 panels were mistakenly duplicated; in [Figure 2A](#F2){ref-type="fig"}, one panel of the 12 panels was also duplicated. The numbers given are correct. The corrected [Figure 1](#F1){ref-type="fig"}, [Figure 2](#F2){ref-type="fig"} and legends appear below.

![TACI Isoforms form hybrid complexes detected by FRET. **(A)** To examine isoform complexes, YFP and mCherry labeled TACI-L, TACI-S, and/or CD40-eYFP as a control, were co-transfected into HEK-293T cells. After 48 h, the molecular association was analyzed by FRET using FACS (LSRII). A minimum of 50,000 positive cells were examined in all experiments. The dot plot results in each panel, are shown for one sample, representative of the results for 6 different experiments. The numerical data given in each panel, are the percent of FRET positive cells, of the live cells in the gate, averaged for all 6 experiments. **(B)** Frequency of FRET positive cells in the double positive YFP and mCherry gate from **(A)**. Graph shows the mean ± SD. \*\*\**p* \< 0.001, two-tailed paired Student *t*-test of 6 independent experiments. **(C)** Either HA-labeled TACI-S or TACI-L transfected into HEK-293T cells, could be precipitated with TACI-L-FLAG as demonstrated in immuno-blotting using anti-HA staining. Lower panel shows FLAG expression as control. **(D)** Addition of increasing amounts of ligands BAFF or APRIL to the TACI-S and TACI-L complexes had no effect on the FRET signal, indicating that receptor assembly in these cells is ligand independent. Data are the mean ± SD from 3 independent experiments.](fimmu-10-02772-g0001){#F1}

![TACI variants with missense mutations bind un-mutated isoforms but lack signaling function. **(A)** TACI mCherry labeled mutants, C104R, A181E, and S194X were generated in the TACI-L and TACI-S isoforms, and co-transfected into HEK**-**293T cells with WT TACI-YFP. These were examined in FRET experiments by FACS (LSRII) to judge complex formation using CD40-eYFP as a control. The dot plot results in each panel, are shown for one sample, representative of the results for 6 different experiments. The numerical data given in each panel, are the percent of FRET positive cells, of the live cells in the gate, averaged for all 6 experiments. **(B)** Frequency of FRET positive cells in the double positive YFP and mCherry gate. Data shows average ± SD from 6 independent experiments. In other experiments, ligands, APRIL, or BAFF (0, 5, 20, or 50 ng/ml) were added to judge the effects on FRET signal, showing no alteration in the signal (not shown). **(C)** For validation of complexes found in FRET, complexes forming with FLAG-TACI were precipitated with anti-FLAG sepharose beads and run on 10% PAGE gels; immunoblots were developed with an anti-HA antibody. Lower panel shows FLAG expression control. **(D)** To examine NF-kB luciferase induction, TACI-S, TACI-L or mutant C104R, A181E and S194X constructs were transfected into HEK-293T cells, along with NF-kB--luc reporter and control pRL-null plasmids and cultured for 48 h; TACI expression was confirmed by western blot. **(E)** These cells were cultured with or without activation for 6 h with 100 ng/ml APRIL or BAFF. Reporter gene activity was determined, and NF-kB luciferase induction normalized to Renilla luciferase. Values reported are represented as Relative Luciferase Activity (RLA) and are the mean ± SD from 5 to 7 independent experiments. \**p* \< 0.05; \*\*\**p* \< 0.001, two-tailed paired Student *t*-test. Western blot shows that all constructions are expressed.](fimmu-10-02772-g0002){#F2}

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
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